(Q33369533)

English

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

Dimosthenis Skarlos

9

object named as

Dimosthenis Skarlos

0 references

Efstathios Kastritis

object named as

Efstathios Kastritis

7

0 references

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

12

0 references

George Fountzilas

5

object named as

George Fountzilas

1 reference

Europe PubMed Central

26 July 2017

Gerassimos Aravantinos

4

object named as

Gerassimos Aravantinos

1 reference

Europe PubMed Central

26 July 2017

Dimitris Pectasides

6

object named as

Dimitris Pectasides

1 reference

Europe PubMed Central

26 July 2017

Helena Linardou

10

object named as

Helena Linardou

1 reference

Europe PubMed Central

26 July 2017

Haralambos P Kalofonos

11

object named as

Haralambos P Kalofonos

1 reference

Europe PubMed Central

26 July 2017

Aristotle Bamias

1

object named as

Aristotle Bamias

1 reference

Europe PubMed Central

26 July 2017

Lia Angela Moulopoulos

2

object named as

Lia A Moulopoulos

1 reference

Europe PubMed Central

26 July 2017

author name string

Aggelos Koutras

3

1 reference

Europe PubMed Central

26 July 2017

Dimitros Gika

8

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

1 January 2006

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

106

1 reference

Europe PubMed Central

26 July 2017

297-303

1 reference

Europe PubMed Central

26 July 2017

2

1 reference

Europe PubMed Central

26 July 2017

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin-based chemotherapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Overview of bladder cancer trials in the European Organization for Research and Treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21604

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21604

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33369533&oldid=1744576264"